Robert Charles Powell, MD, PhD
AUTHOR / RESEARCHER / HISTORIAN / CLINICIAN
Latest release:
Listening Closely to Patients --
without Jumping to Conclusions
{essays on practicing psychiatry} [2021]
Two observational studies:
PART ONE – Differentiation of Moods as a Reflection of Ego Organization and Personality Style: Listening Very, Very Closely as Patients Answer Only Five Questions. [neurotic/ normal, borderline, psychotic]
PART TWO – Erroneous Psychiatric Self-Diagnosis: Non-Psychiatric Patients that Present at a Psychiatrist’s Office.
APPENDIX – Elucidation of Useful Additional Clinical Data.
*****Ascertaining Soft Neurologic Signs.
*****Ascertaining Nutritional Deficits
(Iron Deficiency, Pyridoxine/ B6 Deficiency,
Zinc Deficiency, Vitamin D Deficiency,
Hypercalcemia, Magnesium Deficiency,
Cobalamin/ B12 Deficiency, Hypocalcemia).
*****Ascertaining PreMenstrual Syndrome/ "PMS".]
*****Reconsidering the Relationships of Parts One & Two.
https://www.amazon.com/dp/1542835364/ref=sr_1_1?keywords=listening+closely+to+patients&qid=1627610561&s=books&sr=1-1&asin=B09BG1FYK9&revisionId=b94a9236&format=1&depth=2
Previous latest release:
When Death Is NOT Theoretical: The Readiness of the Music Group ‘Queen’ for Living with Freddie Mercury’s Dying [2nd edition, 2018]
Listening Closely to Patients --
without Jumping to Conclusions
{essays on practicing psychiatry} [2021]
Two observational studies:
PART ONE – Differentiation of Moods as a Reflection of Ego Organization and Personality Style: Listening Very, Very Closely as Patients Answer Only Five Questions. [neurotic/ normal, borderline, psychotic]
PART TWO – Erroneous Psychiatric Self-Diagnosis: Non-Psychiatric Patients that Present at a Psychiatrist’s Office.
APPENDIX – Elucidation of Useful Additional Clinical Data.
*****Ascertaining Soft Neurologic Signs.
*****Ascertaining Nutritional Deficits
(Iron Deficiency, Pyridoxine/ B6 Deficiency,
Zinc Deficiency, Vitamin D Deficiency,
Hypercalcemia, Magnesium Deficiency,
Cobalamin/ B12 Deficiency, Hypocalcemia).
*****Ascertaining PreMenstrual Syndrome/ "PMS".]
*****Reconsidering the Relationships of Parts One & Two.
https://www.amazon.com/dp/1542835364/ref=sr_1_1?keywords=listening+closely+to+patients&qid=1627610561&s=books&sr=1-1&asin=B09BG1FYK9&revisionId=b94a9236&format=1&depth=2
Previous latest release:
When Death Is NOT Theoretical: The Readiness of the Music Group ‘Queen’ for Living with Freddie Mercury’s Dying [2nd edition, 2018]
Most considerations of Queen and its musical catalogue have been by journalists, but Dr. Powell approaches these questions as an historian and clinician, analyzing fifty-some songs and mobilizing extensive amounts of data to support his conclusions. — excerpt from description of When Death is NOT Theoretical, Amazon
2nd ed -- with an Addendum & now an Index -- 40% longer than 1st ed
2nd ed -- with an Addendum & now an Index -- 40% longer than 1st ed
Freddie Mercury -- Brian May -- Roger Taylor -- John Deacon
-- "Bohemian Rhapsody" --
-- "Bohemian Rhapsody" --
COVID-19
See below, under "Works." my booklet:
Pentoxifylline: A Versatile Off-Patent Medication Best Not Overlooked
Some Published Medical Thoughts (as of September 1st, 2020) about
COVID-19 & Pentoxifylline
(a phosphodiesterase 4 inhibitor ) (a production inhibitor of TNF-alpha, IL-6, & IL-2R )
Hendry BM, Stafford N, Arnold AD, et al. “Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID-19 patients.” Pharmacol Res Perspect. 2020 Aug;8(4):e00631; https://pubmed.ncbi.nlm.nih.gov/32715661/ .
Dalamaga M, Karampela I, Mantzoros CS. “Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19.” Metabolism. 2020 Aug;109:154282; https://pubmed.ncbi.nlm.nih.gov/32497535/ .
Giorgi M, Cardarelli S, Ragusa F, et al. “Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19?”. Int J Mol Sci. 2020 Jul;21(15):5338; https://pubmed.ncbi.nlm.nih.gov/32727145/ .
González-Pacheco H, Amezcua-Guerra LM, Sandoval J, Arias-Mendoza “A. Potential usefulness of pentoxifylline, a non-specific phosphodiesterase inhibitor with anti-inflammatory, anti-thrombotic, antioxidant, and anti-fibrogenic properties, in the treatment of SARS-CoV-2.” Eur Rev Med Pharmacol Sci. 2020 Jul;24(13):7494-7496; https://pubmed.ncbi.nlm.nih.gov/32706089/ .
Kanthi Y, Knight JS, Zuo Y, Pinsky DJ. “New (re)purpose for an old drug: purinergic modulation may extinguish the COVID-19 thromboinflammatory firestorm.” JCI Insight. 2020 Jul;5(14):140971; https://pubmed.ncbi.nlm.nih.gov/32530438/ .
Bridgewood C, Damiani G, Sharif K, et al. “Rationale for Evaluating PDE4 Inhibition for Mitigating against Severe Inflammation in COVID-19 Pneumonia and Beyond.” Isr Med Assoc J. 2020 Jun;22(6):335-339; https://pubmed.ncbi.nlm.nih.gov/32558435/ .
See below, under "Works." my booklet:
Pentoxifylline: A Versatile Off-Patent Medication Best Not Overlooked
Some Published Medical Thoughts (as of September 1st, 2020) about
COVID-19 & Pentoxifylline
(a phosphodiesterase 4 inhibitor ) (a production inhibitor of TNF-alpha, IL-6, & IL-2R )
Hendry BM, Stafford N, Arnold AD, et al. “Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID-19 patients.” Pharmacol Res Perspect. 2020 Aug;8(4):e00631; https://pubmed.ncbi.nlm.nih.gov/32715661/ .
Dalamaga M, Karampela I, Mantzoros CS. “Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19.” Metabolism. 2020 Aug;109:154282; https://pubmed.ncbi.nlm.nih.gov/32497535/ .
Giorgi M, Cardarelli S, Ragusa F, et al. “Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19?”. Int J Mol Sci. 2020 Jul;21(15):5338; https://pubmed.ncbi.nlm.nih.gov/32727145/ .
González-Pacheco H, Amezcua-Guerra LM, Sandoval J, Arias-Mendoza “A. Potential usefulness of pentoxifylline, a non-specific phosphodiesterase inhibitor with anti-inflammatory, anti-thrombotic, antioxidant, and anti-fibrogenic properties, in the treatment of SARS-CoV-2.” Eur Rev Med Pharmacol Sci. 2020 Jul;24(13):7494-7496; https://pubmed.ncbi.nlm.nih.gov/32706089/ .
Kanthi Y, Knight JS, Zuo Y, Pinsky DJ. “New (re)purpose for an old drug: purinergic modulation may extinguish the COVID-19 thromboinflammatory firestorm.” JCI Insight. 2020 Jul;5(14):140971; https://pubmed.ncbi.nlm.nih.gov/32530438/ .
Bridgewood C, Damiani G, Sharif K, et al. “Rationale for Evaluating PDE4 Inhibition for Mitigating against Severe Inflammation in COVID-19 Pneumonia and Beyond.” Isr Med Assoc J. 2020 Jun;22(6):335-339; https://pubmed.ncbi.nlm.nih.gov/32558435/ .
